Tony SK Mok, MD, discusses the rationale for the phase 1 U31402-A-U102 trial in metastatic or unresectable non–small cell lung cancer.
Tony S. K. Mok, BMSc, MD, FRCPC
Advertisement
Articles by Tony S. K. Mok, BMSc, MD, FRCPC
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the importance of improving cancer research through collaboration as a Giant of Cancer Care®.
Tony S. K. Mok, MD, BMSc, FRCPC, discusses overall survival from the phase III ALEX trial in ALK-positive lung cancer.
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.
Tony S.K. Mok, BMSc, MD, FRCPC, from the Chinese University of Hong Kong, discusses different plasma testing approaches for patients with lung cancer.
Advertisement
Latest Updated Articles
Dr. Mok on Overall Survival Data From the ALEX Trial in ALK+ Lung CancerPublished: November 1st 2019 | Updated:
Dr. Mok on Plasma Testing Approaches in Lung CancerPublished: August 9th 2013 | Updated:
Dr. Mok Discusses Developing Lung Cancer TreatmentsPublished: September 12th 2013 | Updated:
Dr. Mok on the Importance of Global Collaboration to Improve Cancer CarePublished: December 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5